Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Alnylam Pharmaceuticals Inc
Revenue
Alnylam Pharmaceuticals Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Revenue
$1.8B
|
CAGR 3-Years
55%
|
CAGR 5-Years
89%
|
CAGR 10-Years
44%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Alnylam Pharmaceuticals Inc
Revenue Breakdown
Breakdown by Geography
Alnylam Pharmaceuticals Inc
Breakdown by Segments
Alnylam Pharmaceuticals Inc
Total Revenue:
1.8B
USD
|
Net Product Revenues:
1.2B
USD
|
Net Revenues From Collaborations:
546.2m
USD
|
Royalty Revenue:
40.6m
USD
|
See Also
What is Alnylam Pharmaceuticals Inc's Revenue?
Revenue
1.8B
USD
Based on the financial report for Dec 31, 2023, Alnylam Pharmaceuticals Inc's Revenue amounts to 1.8B USD.
What is Alnylam Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
44%
Over the last year, the Revenue growth was 76%. The average annual Revenue growth rates for Alnylam Pharmaceuticals Inc have been 55% over the past three years , 89% over the past five years , and 44% over the past ten years .